BPC-157 and the Gut: Research Background

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a fragment of the gastric juice protein BPC. Its origin in the gastrointestinal system makes it a subject of considerable pre-clinical research into gut health, intestinal barrier integrity, and gastrointestinal repair mechanisms.

For research use only. Not for human consumption. All findings cited derive from pre-clinical in vitro or animal models.

Intestinal Barrier Function and Tight Junctions

BPC-157 has been shown to upregulate expression of key tight junction proteins including occludin, claudin-1, and ZO-1 in intestinal epithelial cell cultures (Caco-2) exposed to cytokines (TNF-alpha, IL-6). In LPS-stimulated Caco-2 monolayers, BPC-157 treatment (10-100 ng/mL) significantly attenuated the LPS-induced reduction in transepithelial electrical resistance (TEER) and preserved tight junction protein expression at levels comparable to untreated controls.

Intestinal Epithelial Proliferation and Migration

In scratch assays using IEC-6 rat intestinal epithelial cells, BPC-157 at concentrations of 10-1000 pg/mL dose-dependently accelerated wound closure through activation of the FAK-paxillin pathway, which regulates cytoskeletal reorganisation and cell motility.

Inflammatory Bowel Research Models

TNBS Colitis Model

In TNBS intracolonic instillation models (a rodent model of Crohn’s-like colitis), BPC-157 administration reduced macroscopic colonic damage scores, preserved colonic weight-to-length ratios, and attenuated histological markers of inflammation (neutrophil infiltration, ulceration depth) compared to vehicle controls. BPC-157 in TNBS-treated animals was associated with reduced NF-kB p65 expression and lower IL-1beta, TNF-alpha, and IL-6, while anti-inflammatory IL-10 was maintained.

DSS Colitis Model

In dextran sodium sulphate (DSS)-induced colitis (an ulcerative colitis model), BPC-157 reduced disease activity index scores, preserved colon length, and improved histological grade of colonic lesions. BPC-157 appears to modulate COX-2 expression in a tissue-context-dependent manner, yielding anti-inflammatory outcomes in colitis tissue.

Gastric Cytoprotection Models

In rat models of ethanol-induced acute gastric injury, systemic or local BPC-157 administration significantly reduced lesion area via upregulation of eNOS-mediated nitric oxide signalling, promoting gastric mucosal blood flow and mucus secretion. In NSAID-induced gastric damage models (aspirin, indomethacin), BPC-157 pre-treatment attenuated gastric lesion formation through prostaglandin-independent cytoprotective pathways.

BPC-157 Formats for GI Research at Stackpure

Key References

  • Sikiric P et al. (2016). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16):1612-1632.
  • Chang CH et al. (2014). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3):774-780.

All content is for in vitro research reference only. Not for human or veterinary use. Not evaluated by FDA or any regulatory authority.